Dr. Reddy's Laboratories Launches Icosapent Ethyl Capsules, 1 Gram in the US Market
23 June 2021 - - India-based pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) have launched Icosapent Ethyl Capsules, 1 gram approved by the US Food and Drug Administration (USFDA), the company said.

Dr. Reddy's Icosapent Ethyl Capsules, 1 gram is approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. its major markets include USA, India, Russia and CIS countries, and Europe.